As of today (2024-04-23), Haemonetics's share price is $85.13.
Haemonetics's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 was $3.85. Hence, Haemonetics's Price-to-Operating-Cash-Flow Ratio for today is 22.14.
The historical rank and industry rank for Haemonetics's Price-to-Operating-Cash-Flow or its related term are showing as below:
HAE'
s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 10.51 Med: 18.39 Max: 60.98
Current: 22.13
During the past 13 years, Haemonetics's highest Price-to-Operating-Cash-Flow Ratio was 60.98. The lowest was 10.51. And the median was 18.39.
Haemonetics's Cash Flow from Operations per share for the
three
months ended in Dec. 2023 was $-0.01.
Its Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 was $3.85.
During the past 12 months, the average Operating Cash Flow per Share Growth Rate of Haemonetics was -24.40% per year.
During the past 3 years, the average Operating Cash Flow per Share Growth Rate was 20.30% per year.
During the past 5 years, the average Operating Cash Flow per Share Growth Rate was 3.60% per year.
During the past 10 years, the average Operating Cash Flow per Share Growth Rate was 6.40% per year.
During the past 13 years, Haemonetics's highest 3-Year average Operating Cash Flow per Share Growth Rate was 41.80% per year. The lowest was -19.80% per year. And the median was 5.70% per year.
Haemonetics Price-to-Operating-Cash-Flow Historical Data
The historical data trend for Haemonetics's Price-to-Operating-Cash-Flow can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
|
Haemonetics Annual Data
|
|
Trend |
Mar14 |
Mar15 |
Mar16 |
Mar17 |
Mar18 |
Mar19 |
Mar20 |
Mar21 |
Mar22 |
Mar23 |
| Price-to-Operating-Cash-Flow |
|
Get a 7-Day Free Trial
|
|
|
29.07 |
32.64 |
52.34 |
18.85 |
15.58 |
|
Haemonetics Quarterly Data
|
|
Mar19 |
Jun19 |
Sep19 |
Dec19 |
Mar20 |
Jun20 |
Sep20 |
Dec20 |
Mar21 |
Jun21 |
Sep21 |
Dec21 |
Mar22 |
Jun22 |
Sep22 |
Dec22 |
Mar23 |
Jun23 |
Sep23 |
Dec23 |
| Price-to-Operating-Cash-Flow |
Get a 7-Day Free Trial
|
|
|
|
|
|
|
|
|
|
|
|
|
15.47 |
15.58 |
17.48 |
17.52 |
22.24 |
Competitive Comparison
For the Medical Instruments & Supplies subindustry, Haemonetics's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Haemonetics Price-to-Operating-Cash-Flow Distribution
For the Medical Devices & Instruments industry and Healthcare sector, Haemonetics's Price-to-Operating-Cash-Flow distribution charts can be found below:
* The bar in red indicates where Haemonetics's Price-to-Operating-Cash-Flow falls into.
Haemonetics Price-to-Operating-Cash-Flow Calculation
Haemonetics's Price-to-Operating-Cash-Flow ratio for today is calculated as
| Price-to-Operating-Cash-Flow Ratio | = | Share Price | / | Cash Flow from Operations per share (TTM) |
| = | 85.13 | / | 3.845 |
| = | 22.14 |
Haemonetics's Share Price of today is $85.13.
Haemonetics's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $3.85.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: Cash Flow from Operations per share is calculated as Cash Flow from Operations divided by Shares Outstanding (Diluted Average).
It can also be calculated from the numbers for the whole company:
Haemonetics (Haemonetics) Business Description
Traded in Other Exchanges
Address
125 Summer Street, Boston, MA, USA, 02110
Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The company places primary emphasis on its plasma and hospital segments due to their robust growth potential, whereas the blood center segment tends to be constrained by higher competition. Product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality.
Executives
| Stewart W Strong |
officer: President, Global Hospital |
C/O HAEMONETICS CORPORATION, 125 SUMMER STREET, BOSTON MA 02110 |
| Anila Lingamneni |
officer: EVP, Chief Technology Officer |
HAEMONETICS CORPORATION, 125 SUMMER STREET, BOSTON MA 02110 |
| Charles J Dockendorff |
director |
COVIDIEN LTD., 15 HAMPSHIRE STREET, MANSFIELD MA 02048 |
| Diane M Bryant |
director |
2200 MISSION COLLEGE BLVD, SANTA CLARA CA 95054 |
| Josep Llorens |
officer: EVP, Global Manufacturing |
HAEMONETICS CORPORATION, 400 WOOD ROAD, BRAINTREE MA 02184 |
| Michelle L Basil |
officer: EVP and General Counsel |
HAEMONETICS CORPORATION, 400 WOOD ROAD, BRAINTREE MA 02184 |
| Farris Maryanne Maunsell |
officer: VP, Chief Accounting Officer |
C/O HAEMONETICS CORPORATION, 125 SUMMER STREET, BOSTON MA 02110 |
| Roy Galvin |
officer: President, Global Plasma & BC |
C/O HAEMONETICS CORPORATION, 125 SUMMER STREET, BOSTON MA 02110 |
| Laurie A. Miller |
officer: SVP, Human Resources |
C/O HAEMONETICS CORPORATION, 125 SUMMER STREET, BOSTON MA 02110 |
| Mark W Kroll |
director |
PO BOX 23, CRYSTAL BAY MN 55323 |
| Dan Goldstein |
officer: VP, Corporate Controller |
HAEMONETICS CORPORATION, 400 WOOD ROAD, BRAINTREE MA 02184 |
| Christopher Simon, |
director, officer: President & CEO |
HAEMONETICS CORPORATION, 400 WOOD ROAD, BRAINTREE MA 02184 |
| James Darecca |
officer: EVP, Chief Financial Officer |
C/O HAEMONETICS CORPORATION, 125 SUMMER STREET, BOSTON MA 02110 |
| Burke William P. Mr. |
officer: EVP, Chief Financial Officer |
HAEMONETICS CORPORATION, 400 WOOD ROAD, BRAINTREE MA 02184 |
| Lloyd Emerson Johnson |
director |
16737 NEW PROVIDENCE LANE, CHARLOTTE NC 28277 |
Haemonetics (Haemonetics) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
HAE has been successfully added to your